TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med, 10.1016/S2213-2600(20)30076-X Zenewicz, 2018, IL-22: there is a gap in our knowledge, Immunohorizons, 2, 198, 10.4049/immunohorizons.1800006 Tse, 2004, Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS), J Clin Pathol, 57, 260, 10.1136/jcp.2003.013276 Faure, 2014, Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?, PLoS One, 9, e88716, 10.1371/journal.pone.0088716 Josset, 2013, Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus, mBio, 4, 10.1128/mBio.00165-13 Bermejo-Martin, 2009, Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza, Crit Care, 13, R201, 10.1186/cc8208 Li, 2012, IL-17 response mediates acute lung injury induced by the 2009 pandemic influenza A (H1N1) virus, Cell Res, 22, 528, 10.1038/cr.2011.165 Fabbi, 2017, Dual roles of IL-27 in cancer biology and immunotherapy, Mediat Inflamm, 2017, 3958069, 10.1155/2017/3958069 Bright, 1999, Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis, J Immunol, 162, 6255, 10.4049/jimmunol.162.10.6255